Novavax’s COVID-19 vaccine is more than 90% effective, including against coronavirus variations, according to a large-scale US research released Monday. The vaccine “demonstrated 100 % protection against moderate and severe disease, with an overall efficacy of 90.4%,” according to the company, which added that “the study enrolled 29,960 participants across 119 sites in the United States and Mexico to evaluate the efficacy, safety, and tolerability.”
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” said Stanley C. Erck, Novavax’s president and chief executive.
The company, which is based in Maryland, said it plans to file for regulatory permission in the third quarter of 2021. Following that, the company stated that it would be on track to produce 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.
While some wealthy countries have made headway in immunising their citizens, there are still concerns that many poorer countries will be left out of the global vaccination campaign. Vaccination rates in the world’s poorest countries lag well behind those of the Group of Seven industrialised powers and other wealthy nations — in terms of doses delivered thus far, the disparity between the G7 and the rest of the world is staggering.
Novavax’s vaccine, formally known as NVX-CoV2373, does not require storage at ultra-low temperatures, unlike other rival vaccines. It was “stored and stable at 2°- 8°C, permitting the use of current vaccine supply chain channels for its distribution,” according to the company.